[CH3:1][NH:2][C:3](=[O:15])[C:4]([C:8]1[CH:13]=[CH:12][CH:11]=[CH:10][C:9]=1[OH:14])=[N:5][O:6][CH3:7].C(=O)([O-])[O-].[K+].[K+].[F:22][C:23]1[C:28]([F:29])=[C:27](F)[N:26]=[CH:25][N:24]=1>C(#N)C>[CH3:1][NH:2][C:3](=[O:15])[C:4]([C:8]1[CH:13]=[CH:12][CH:11]=[CH:10][C:9]=1[O:14][C:27]1[C:28]([F:29])=[C:23]([F:22])[N:24]=[CH:25][N:26]=1)=[N:5][O:6][CH3:7]6 g (0.0280 mol) of N-methyl-2-(2-hydroxyphenyl)-2-methoxyiminoacetamide (Example I-1g from process step 1; HPLC: 43.7% N-methyl-E-2-(2-hydroxyphenyl)-2-methoxyimino-acetamide of log p=0.98 and 53.5% N-methyl-Z-2-(2-hydroxyphenyl)-2-methoxyiminoacetamide of log p=1.29) are dissolved in 80 ml of acetonitrile. The solution is cooled to 0° C., 4.7 g (0.034 mol) of potassium carbonate are added and the mixture is stirred for another 30 minutes. 3.8 g (0.0283 mol) of 4,5,6-trifluoropyrimidine are then added dropwise and the mixture is stirred at 20° C. for two hours. The solvent is then distilled off under reduced pressure, the residue is mixed with water, the product is extracted with ethyl acetate, the organic phase is dried over sodium sulphate and the solvent is distilled off under reduced pressure. This gives 5.7 g (61.4% of theory) of crude N-methyl-2-[2-(5,6-difluoropyrimidin-4-yloxy)phenyl]-2-methoxyiminoacetamide which, according to HPLC, contains 45.5% N-methyl-E-2-[2-(5,6-difluoropyrimidin-4-yloxy)-phenyl]-2-methoxyiminoacetamide of log p=1.95 and 46.6% N-methyl-Z-2-[2-(5,6-difluoro-pyrimidin-4-yloxy)phenyl]-2-methoxyiminoacetamide of log p=1.87.
読み込み中…
